{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-26-000005","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.361422+00:00","generated_at":"2026-05-16T00:26:08.825709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Maravai Q4 revenue $49.9M, net loss $63M; guides 2026 revenue $200-210M","bullets":["Q4 revenue $49.9M, net loss $(63.0)M, positive Adj EBITDA $0.5M (non-GAAP).","Full year 2025 revenue $185.7M, net loss $(230.8)M, Adj EBITDA $(31.2)M.","Introduces 2026 revenue guidance $200M-$210M and Adj EBITDA guidance $18M-$20M.","CEO cites strong execution, exceeding revenue expectations, returning to positive Adj EBITDA.","Organizational restructuring and operating cost reduction ahead of plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-26-000005","json":"https://secwatch.observer/filing/0001823239-26-000005.json","markdown":"https://secwatch.observer/filing/0001823239-26-000005.md","text":"https://secwatch.observer/filing/0001823239-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000005/0001823239-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000005/mrvi-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:26:08.825709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}